Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

252 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.
Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Kitamura H, Kamoto T, Eto M; Japanese Urological Oncology Group. Tanegashima T, et al. Among authors: kuroiwa k. Int J Clin Oncol. 2024 Dec 17. doi: 10.1007/s10147-024-02681-2. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39688742
High Ki-67 Expression Predicting a Risk Factor for the Progression of Disease within 24 Months and Microenvironment in Follicular Lymphoma.
Narita H, Kuroiwa K, Kawaguchi Y, Murai S, Sasaki Y, Homma M, Kawamata N, Hayashi H, Nagao K, Okamura R, Uesugi Y, Sasaki Y, Shimada S, Watanuki M, Arai N, Yanagisawa K, Shiozawa E, Yamochi T, Hattori N. Narita H, et al. Among authors: kuroiwa k. Int J Mol Sci. 2024 Oct 15;25(20):11057. doi: 10.3390/ijms252011057. Int J Mol Sci. 2024. PMID: 39456838 Free PMC article.
Fludarabine Melphalan, Reduced-dose Busulfan Versus Fludarabine, Melphalan, Full-dose Busulfan in Patients Receiving Cord Blood Transplantation.
Arai N, Narita H, Kuroiwa K, Nagao K, Hayashi H, Kawamata N, Okamura R, Sasaki Y, Shimada S, Watanuki M, Kawaguchi Y, Yanagisawa K, Hattori N. Arai N, et al. Among authors: kuroiwa k. Transplant Proc. 2024 Oct;56(8):1828-1835. doi: 10.1016/j.transproceed.2024.08.031. Epub 2024 Sep 3. Transplant Proc. 2024. PMID: 39232926
Efficacy of avelumab maintenance therapy for advanced urothelial carcinoma with histologic subtype and divergent differentiation: a multicenter retrospective study conducted by the Uro-Oncology Group in Kyushu.
Minato A, Furubayashi N, Tomoda T, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Tomisaki I, Harada K, Nakamura M, Fujimoto N. Minato A, et al. Among authors: kuroiwa k. Transl Androl Urol. 2024 Jul 31;13(7):1118-1126. doi: 10.21037/tau-24-53. Epub 2024 Jul 12. Transl Androl Urol. 2024. PMID: 39100842 Free PMC article.
Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status.
Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Song Y, Harada K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M; Uro-Oncology Group in Kyushu (UROKYU). Furubayashi N, et al. Among authors: kuroiwa k. Anticancer Res. 2024 Aug;44(8):3409-3417. doi: 10.21873/anticanres.17161. Anticancer Res. 2024. PMID: 39060060
Organ-Specific Tumor Response to Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.
Minato A, Furubayashi N, Tomoda T, Masaoka H, Song Y, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K, Seki N, Tomisaki I, Harada K, Nakamura M, Fujimoto N. Minato A, et al. Among authors: kuroiwa k. Clin Genitourin Cancer. 2024 Oct;22(5):102148. doi: 10.1016/j.clgc.2024.102148. Epub 2024 Jul 2. Clin Genitourin Cancer. 2024. PMID: 39033710 Free article.
252 results